NanoViricides (NYSE:NNVC) Now Covered by Analysts at started coverage on shares of NanoViricides (NYSE:NNVCFree Report) in a research report report published on Tuesday morning. The firm issued a sell rating on the stock.

NanoViricides Stock Up 1.8 %

NanoViricides stock opened at $1.14 on Tuesday. The company’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.16. NanoViricides has a twelve month low of $1.00 and a twelve month high of $2.00. The company has a market cap of $13.43 million, a PE ratio of -1.41 and a beta of 0.68.

NanoViricides (NYSE:NNVCGet Free Report) last posted its earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.

Featured Stories

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with's FREE daily email newsletter.